Publication Date:
2006-11-16
Description:
It is very important and difficult to study and research the safety and effective methods of treatment in the Terminal or refractory Non-Hodgkin’s Lymphoma ( NHL)patients, especially old patients. To evaluate the safety and efficacy of Rituximab in Combination with MEVP Chemotherapy and rhG-CSF in old patients of Refractory and Terminal Non-Hodgkin’s Lymphoma, 4 old patients of Refractory and Terminal Non-Hodgkin’s Lymphoma( disease history about 6~8 years),3 females and 1 male, between 66~75 years of age (mean age 70.5 years), 2cases IVB, 1 cases IVA, 1case IIIA., Superficial and deep multiple lymph nodes enlarged obviously in all patients and 3 cases of them showed multiple lymph node enlargement and marked lumps in abdominal cavity, 2 cases of them with hydrothorax and ascites, 2 cases of them with bone marrow infiltration and heart disease, 1 case of them with multiple lumps in liver and another of them with autoimmune hemolytic anemia (AIHA), All patients had been treated with chemotherapy included COP (or COPP), CHOP, BCAOP (or BECAOP), MIV (or ESHAP) etc. and 2 patients of them had been treated by radiotherapy before they were treated by Rituximab Combination with MEVP Chemotherapy and rhG-CSF. In this experiment, they were treated by Rituximab plus MEVP Chemotherapy and rhG-CSF,( Rituximab 375 mg/m2/d1, Mitoxantrone 8~10mg/m2/d3, Wumon 0.1/d3~d5 (or VP16 O.1/d3~d7), Vinorelbinum 20mg/m2/d3, Prednison 60mg/d3~d9), rhG-CSF 100~300/d were injected when the number of WBC was
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink